As the omicron variant of the coronavirus continues to spread, shareholders have filed 16 resolutions at pharmaceutical manufacturers related to the equitable access to COVID-19 vaccines.
Mercy Investment Services is an active member of the Interfaith Center on Corporate Responsibility and the co-founder of the Investors for Opioid and Pharmaceutical Accountability. The two organizations collaboratively filed 16 resolutions at seven pharmaceutical companies addressing COVID-19 vaccines and therapeutics. Shareholders are concerned with the companies’ staunch resistance to facilitating vaccine manufacturing by generics-producing companies, increasing global access. Mercy Investment Services filed seven resolutions, leading four, including asking how companies oversee risks related to anti-competitive practices. Other resolutions at the pharma companies address lobbying, consideration of public investment in vaccine development, racial equity audits, and the transfer of intellectual property to expand vaccine production.
Mercy Investment Services is closely monitoring company responses to these resolutions and will continue to engage them to ensure equitable access to COVID-19 vaccines.